Scisparc secures strategic advantage with grant of european patent

Tel aviv, israel, may 31, 2024 (globe newswire) -- scisparc ltd. (nasdaq: sprc) (“company” or “scisparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that the european patent office granted the company's patent application titled “compositions and methods of potentiating antimicrobials”. this is in addition to the patent titled “compositions and methods of potentiating antimicrobials” previously granted by the united states patent and trademark office. this patent grant bolsters the company's intellectual property portfolio, extending the protection of its global patent holdings.
SPRC Ratings Summary
SPRC Quant Ranking